Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024
March 18, 2024 16:01 ET
|
Carina Biotech Limited
ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from...
Carina Biotech Doses First Patient in Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy
December 18, 2023 17:30 ET
|
Carina Biotech Limited
First patient dosed in Australia where 3 clinical trial sites have been activated.The trial will enrol advanced colorectal cancer patients whose cancer expresses the cancer stem cell marker LGR5, and...
Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Human Cancer Models at 8th CAR-TCR Summit
August 21, 2023 08:00 ET
|
Carina Biotech Limited
LGR5 is expressed, both in vitro and in vivo, by numerous human cancers, including colorectal, ovarian, gastric, brain, and pancreatic cancer. LGR5-targeting CAR-T cells effectively kill...
Carina Biotech Appoints Two New U.S. Based Biotechnology Executives to the Board of Directors
June 05, 2023 08:00 ET
|
Carina Biotech Limited
ADELAIDE, Australia, June 05, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment of Michael S. Wyzga, M.B.A., and Remus Vezan...
Carina Biotech to Participate in Three Upcoming Conferences
May 24, 2023 18:00 ET
|
Carina Biotech Limited
ADELAIDE, Australia, May 24, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced that the management team will participate in the three upcoming...
Carina Biotech to Present Details of Planned Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate CNA3103 for Metastatic Colorectal Cancer at 2023 ASCO Annual Meeting
May 01, 2023 16:30 ET
|
CARINA BIOTECH PTY LTD
First in human, multicenter, open label, Phase 1/2a dose escalation and expansion study to determine the safety of and overall best response to CNA3103 in subjects with mCRCPhase 1 segment of the...
Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Colorectal Cancer Models at 2023 AACR
March 21, 2023 18:30 ET
|
CARINA BIOTECH PTY LTD
Preclinical data demonstrates that LGR5-targeting CAR-T therapy has high potential as an effective therapeutic for human colorectal cancer.LGR5-targeting CAR-T cells effectively kill LGR5-expressing...
Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T Cell Therapy Platform in Ovarian Cancer Tumor Models
February 06, 2023 18:14 ET
|
CARINA BIOTECH PTY LTD
Preclinical evidence shows that LGR5 targeted CAR-T cells are able to kill ovarian cancer cells and to reduce ovarian cancer tumor burden in animal modelsThe data suggests that LGR5 CAR-T cells have...
Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate for Treatment of Advanced Colorectal Cancer
January 23, 2023 18:55 ET
|
CARINA BIOTECH PTY LTD
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103On track to commence patient enrollment during the first half 2023 ADELAIDE, Australia , Jan. 23,...
Carina Biotech Submits an Investigational New Drug (IND) Application to US FDA for LGR5-Targeted CAR-T Cell Therapy Candidate
December 12, 2022 20:34 ET
|
CARINA BIOTECH PTY LTD
HIGHLIGHTS Files its first IND application for a CAR-T cell therapy targeting a solid cancer. The IND application is directed at a first-in-human Phase 1/2a clinical trial in advanced colorectal...